LON:SAR Sareum (SAR) Share Forecast, Price & News GBX 80 0.00 (0.00%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range 78▼ 8350-Day Range 72.50▼ 105.5052-Week Range 55.10▼ 237.50Volume45,724 shsAverage Volume83,659 shsMarket Capitalization£56.06 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 304 ProfileProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines Sareum MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside280.0% UpsideGBX 304 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares£203,278 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.59 out of 5 stars 3.5 Analyst's Opinion Consensus RatingSareum has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 304, Sareum has a forecasted upside of 280.0% from its current price of GBX 80.Amount of Analyst CoverageSareum has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SAR. Previous Next 0.0 Dividend Strength Dividend YieldSareum does not currently pay a dividend.Dividend GrowthSareum does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SAR. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 4 people have searched for SAR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added Sareum to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sareum insiders have bought more of their company's stock than they have sold. Specifically, they have bought £2,032.78 in company stock and sold GBX 0 in company stock.Percentage Held by InsidersOnly 6.29% of the stock of Sareum is held by insiders.Percentage Held by InstitutionsOnly 0.06% of the stock of Sareum is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Sareum is -2,000.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sareum is -2,000.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSareum has a P/B Ratio of 20.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sareum (LON:SAR) StockSareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes TYK2/JAK1 kinase, which is in preclinical stage; Checkpoint Kinase 1, which has completed clinical phase II; and FLT3+Aurora kinase, which is in preclinical stage. The company was founded in 2003 and is headquartered in Cambridge, the United Kingdom.Read More SAR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAR Stock News HeadlinesSeptember 5, 2023 | msn.comSareum doses first subjects in second stage of Phase 1a trial of SDC-1801September 4, 2023 | lse.co.ukSareum begins dosing participants in phase 1a trial for SDC-1801September 29, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. August 22, 2023 | msn.com25 Best Netflix Movies Based On True StoriesJuly 15, 2023 | msn.comNetflix: The thriller written by Angelina Jolie that is all the rage on the platform in the USJune 26, 2023 | lse.co.ukTRADING UPDATES: New patents for Sareum; Guanajuato hails assessmentJune 22, 2023 | marketwatch.comA thorough analysis of the Anaplastic Large Cell Lymphoma Treatment market Size with projected 13.7% CAGR growth from 2023 to 2030June 16, 2023 | ft.comFresh blow to City as WE Soda pulls $7.5bn London IPOSeptember 29, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. May 25, 2023 | finance.yahoo.comSAR.L - Sareum Holdings plcMay 18, 2023 | lse.co.ukTRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effectApril 27, 2023 | finance.yahoo.comWe're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn RateApril 17, 2023 | marketwatch.comNON RECEPTOR TYROSINE PROTEIN KINASE TYK2 Market Size by 2031April 7, 2023 | marketwatch.comNon Receptor Tyrosine Protein Kinase TYK2 Market Demand by 2030March 30, 2023 | uk.news.yahoo.comShould I get invested in this FTSE pharma share?March 2, 2023 | marketwatch.comNew Market Report on Anaplastic Large Cell Lymphoma Comes With A Thorough Analysis Of Industry Trends, Share, Size.February 7, 2023 | finance.yahoo.comFollowing a 32% decline over last year, recent gains may please Sareum Holdings plc (LON:SAR) institutional ownersJanuary 23, 2023 | marketwatch.comNON RECEPTOR TYROSINE PROTEIN KINASE TYK2 Market Evolution Segmentation and Insight of Trends 2023 to 2028 with Top Countries DataOctober 25, 2022 | finance.yahoo.comSareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth PlansOctober 14, 2022 | msn.comSMALL CAP MOVERS: Property lender Lendinvest sinks 36% to a new low of 64p over risk of falling property prices; Cybersecurity firm Intercede surges 39% - msnNOWOctober 13, 2022 | lse.co.ukGlaxosmithkline News Headlines. GSK Share News. Financial News Articles for Gsk Plc Ord 31 1/4P updated throughout the day. - London South EastOctober 12, 2022 | marketscreener.comSareum Plunges 19% Amid GSK Unit's Plan To Return Cancer Medication Rights To CRT Pioneer Fund - Marketscreener.comOctober 12, 2022 | lse.co.ukNigeria's Forcados crude loadings to restart by end of October - SPDC | Financial News - London South EastOctober 12, 2022 | marketwatch.comSareum Holdings Says Sierra Oncology To Return Cancer Treatment License; Shares Fall - MarketWatchSeptember 13, 2022 | proactiveinvestors.com.auSmall Cap Feast - Critical Metals, Nightcap, Sareum Holdings, Spectra Systems, Altona Rare Earths and more... - Proactive Investors AustraliaSeptember 13, 2022 | morningstar.co.ukCORRECT: Sareum notes US FDA approval of Bristol-Myers's Sotyktu - MorningstarSeptember 12, 2022 | morningstar.co.ukSareum receives US US Food & Drug Administration approval for Sotyktu - MorningstarSee More Headlines Receive SAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:SAR CUSIPN/A CIKN/A Webwww.sareum.co.uk Phone+44-1223-497700FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 304 High Stock Price ForecastGBX 304 Low Stock Price ForecastGBX 304 Forecasted Upside/Downside+280.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-64.48% Return on Assets-44.84% Debt Debt-to-Equity RatioN/A Current Ratio7.22 Quick Ratio10.37 Sales & Book Value Annual Sales£47,204.00 Price / Sales1,187.53 Cash FlowGBX 7.06 per share Price / Cash Flow11.32 Book ValueGBX 4 per share Price / Book20.00Miscellaneous Outstanding Shares70,070,000Free FloatN/AMarket Cap£56.06 million OptionableNot Optionable Beta-0.51 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Tim J. Mitchell Ph.D. (Age 63)Founder, CEO & Exec. Director Comp: $189.6kDr. John C. Reader Ph.D. (Age 56)Founder, Chief Scientific Officer & Exec. Director Comp: $187.14kMr. Clive H. W. Birch F.C.A. (Age 69)Sr. Independent Non-Exec. Director & Sec. Comp: $20kAlexandra HarrisonHead of IRKey CompetitorsArecor TherapeuticsLON:ARECOxford BioDynamicsLON:OBDDestiny PharmaLON:DESTOpen OrphanLON:ORPHTissue Regenix GroupLON:TRXView All CompetitorsInsidersClive BirchBought 2,479 shares on 9/4/2023Total: £203,278.00 ($82.00/share)Stephen ParkerBought 19,972 shares on 12/28/2022Total: £1.56 M ($78.00/share)View All Insider Transactions SAR Stock - Frequently Asked Questions Should I buy or sell Sareum stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sareum in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SAR shares. View SAR analyst ratings or view top-rated stocks. What is Sareum's stock price forecast for 2023? 1 Wall Street research analysts have issued 1-year price objectives for Sareum's stock. Their SAR share price forecasts range from GBX 304 to GBX 304. On average, they expect the company's stock price to reach GBX 304 in the next twelve months. This suggests a possible upside of 280.0% from the stock's current price. View analysts price targets for SAR or view top-rated stocks among Wall Street analysts. How have SAR shares performed in 2023? Sareum's stock was trading at GBX 82.50 at the beginning of the year. Since then, SAR shares have decreased by 3.0% and is now trading at GBX 80. View the best growth stocks for 2023 here. What other stocks do shareholders of Sareum own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sareum investors own include ReNeuron Group (RENE), ValiRx (VAL), Sierra Oncology (SRRA), Egdon Resources (EDR), Collagen Solutions plc (COS.L) (COS), Gulf Keystone Petroleum (GKP), Madagascar Oil (MOIL), Summit Therapeutics (SMMT), Rockhopper Exploration (RKH) and What is Sareum's stock symbol? Sareum trades on the London Stock Exchange (LON) under the ticker symbol "SAR." How do I buy shares of Sareum? Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Sareum's stock price today? One share of SAR stock can currently be purchased for approximately GBX 80. How much money does Sareum make? Sareum (LON:SAR) has a market capitalization of £56.06 million and generates £47,204.00 in revenue each year. The company earns £-2,760,000.00 in net income (profit) each year or GBX (0.04) on an earnings per share basis. How can I contact Sareum? Sareum's mailing address is Unit 2A Langford Arch, London Road, Pampisford, CAMBRIDGE, CB22 3FX, United Kingdom. The official website for the company is www.sareum.co.uk. The company can be reached via phone at +44-1223-497700. This page (LON:SAR) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sareum Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.